Currently, we have reached the end of patient recruitment for a new randomized myeloma trial and once survival data are available, we will validate the VISTA-associated T-cell exclusion score in this large cohort, and at the same time, further delineate which cell type within CD11b+ cells shows the highest expression of VISTA. This evidence concerns the gene ITGAM and plasma cell myeloma.